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Translational Relevance 
BRAF mutations occur in approximately 50% of melanoma cases. Treatment with 
currently approved BRAF inhibitors (BRAFis) in patients with BRAF-mutant 
melanoma results in disease progression within 6-8 months of starting treatment. 
Combined therapies of BRAF and MEK inhibitors (dabrafenib + trametinib; 
vemurafenib + cobimetinib) have been approved after demonstrating superior 
efficacy compared with BRAFi monotherapy. Encorafenib (LGX818), a selective 
BRAFi, was evaluated preclinically and in a single-agent phase I clinical study. 
Encorafenib showed more potent and prolonged pharmacodynamic activity 
compared with vemurafenib and dabrafenib. Clinical activity was observed in both 
BRAFi-pretreated and BRAFi-naive patients at the recommended phase II dose (300 
mg QD). The safety profile was distinct compared with other approved BRAFis, with 
lower rates of cutaneous squamous cell carcinoma and photosensitivity, but higher 
rates of Palmar-Plantar Erythrodysthesia and facial paresis. These findings highlight 
the potential of encorafenib in the treatment of BRAF-mutant melanoma in future 
combination studies. 
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Abstract 
 
Purpose: Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacological 
profile that is distinct from that of other clinically active BRAFis. We evaluated 
encorafenib in a phase I study in patients with BRAFi treatment-naive and pretreated 
BRAF-mutant melanoma. 
Experimental Design: The pharmacological activity of encorafenib was first 
characterized preclinically. Encorafenib monotherapy was then tested across a 
range of once-daily (QD; 50-700 mg) or twice-daily (75-150 mg) regimens in a 
phase I, open-label, dose-escalation and -expansion study in adult patients with 
histologically confirmed advanced/metastatic BRAF-mutant melanoma. Study 
objectives were to determine the maximum tolerated dose (MTD) and/or 
recommended phase II dose (RP2D), characterize the safety and tolerability and 
pharmacokinetic profile, and assess the preliminary antitumor activity of encorafenib. 
Results: Preclinical data demonstrated that encorafenib inhibited BRAF V600E 
kinase activity with a prolonged off-rate and suppressed proliferation and tumor 
growth of BRAF V600E-mutant melanoma models. In the dose-escalation phase, 
54 patients (29 BRAFi-pretreated and 25 BRAFi-naïve) were enrolled. Seven 
patients in the dose-determining set experienced dose-limiting toxicities. Encorafenib 
at a dose of 300 mg QD was declared the RP2D. In the expansion phase, the most 
common all-cause adverse events were nausea (66%), myalgia (63%), and palmar-
plantar erythrodysesthesia (54%). In BRAFi-naive patients, the overall response rate 
(ORR) and median progression-free survival (mPFS) were 60% and 12.4 months 
(95% CI, 7.4-NR). In BRAFi-pretreated patients, the ORR and mPFS were 22% and 
1.9 months (95% CI, 0.9-3.7). 
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Conclusions: Once-daily dosing of single-agent encorafenib had a distinct 
tolerability profile and showed varying antitumor activity across BRAFi-pretreated 
and BRAFi-naive patients with advanced/metastatic melanoma. 
 
  
Research. 
on August 28, 2017. © 2017 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 13, 2017; DOI: 10.1158/1078-0432.CCR-16-2923 
6 
 
INTRODUCTION 
Melanoma is responsible for the majority of skin cancer deaths worldwide (1), and 
approximately 232,000 new cases of melanoma were diagnosed in 2012 (2). Most 
melanomas harbor alterations in components of the RAF/MEK/mitogen-activated 
protein kinase (MAPK) signaling transduction pathway, which drives cell proliferation, 
differentiation, and survival and can therefore lead to malignant cell proliferation (3).  
 
Mutations in the BRAF gene occur in approximately 50% of melanoma cases (4). 
Over 90% of BRAF mutations are valine 600 substitutions (V600) (4). Vemurafenib 
and dabrafenib are currently the only approved BRAF inhibitors (BRAFis) for the 
treatment of BRAF V600-mutant melanoma (5-8). Unfortunately, most patients 
treated with BRAFis develop resistance and exhibit disease progression within 6-8 
months of starting therapy, despite substantial initial tumor regression (9). Dual 
inhibition of the MAPK pathway with combined BRAF and MEK inhibitors have 
become the new standard of care in melanoma therapy following the approval of 
dabrafenib plus trametinib, and vemurafenib plus cobimetinib combination therapies, 
which demonstrated superior response to single-agent BRAFis in advanced 
melanoma (10-13). 
 
BRAFis are associated with a number of proliferative and malignant cutaneous side 
effects, including cutaneous squamous cell carcinomas (SCC) and 
keratoacanthomas. Paradoxical activation of wild-type BRAF/CRAF is proposed to 
be the underlying mechanism of these adverse effects (AEs) (14). Highly selective 
BRAFis that are effective at low doses and with fewer side effects are ideal 
candidates for both single-agent and combination treatments. Encorafenib is a 
Research. 
on August 28, 2017. © 2017 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 13, 2017; DOI: 10.1158/1078-0432.CCR-16-2923 
7 
 
potent, selective RAF kinase inhibitor with promising activity in preclinical models, 
including increased potency compared with vemurafenib (15). Presented here are 
results from preclinical studies demonstrating the pharmacologic properties of 
encorafenib as well as a phase I dose-escalation and dose-expansion study of 
single-agent encorafenib in patients with metastatic BRAF-mutant melanoma.  
 
METHODS 
Pharmacologic characterization of encorafenib in preclinical models 
The potency of encorafenib, vemurafenib, and dabrafenib were measured in 
biochemical assays using methods previously described (16). Inhibition of BRAF 
V600E was evaluated in cell lines and xenograft tumors by measuring 
phosphorylated ERK (pERK) and total ERK using an immunoassay (Meso Scale 
Discovery). Cell proliferation assays were performed following 3 days of drug 
exposure with viability measured using CellTiter Glo 2.0. Mouse xenograft studies 
were performed in 6- to 8-week-old female nude mice following subcutaneous 
implantation of A375 cells (5 × 106) in 50% Matrigel or 3-mm × 3-mm pieces of the 
HMEX1906 primary human melanoma xenograft model. All laboratory animal work 
was conducted following appropriate laws and guidelines of the US Department of 
Agriculture, Office of Laboratory Animal Welfare, Association for Assessment and 
Accreditation of Laboratory Animal Care, and the Guide for the Care and Use of 
Laboratory Animals. 
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Phase I clinical trial 
Patient eligibility 
Key inclusion criteria were: age ≥18 years old; evaluable, histologically confirmed, 
locally advanced/metastatic BRAF V600-mutant melanoma (unresectable stage IIIB-
IV); and World Health Organization performance status ≤2. Key exclusion criteria 
were: prior MEK inhibitor therapy; prior systemic anticancer treatment ≤4 weeks, or 
major surgery ≤2 weeks prior to starting the study; symptomatic/untreated 
leptomeningeal disease or brain metastases; acute/chronic pancreatitis; clinically 
significant cardiac disease; or impairment of gastrointestinal function. All patients 
were required to provide written informed consent obtained before any screening 
procedure. This study was conducted according to the ethical principles of the 
Declaration of Helsinki. 
Study design and treatments 
This phase I open-label, multicenter study included a dose-escalation and  
-expansion phase (NCT01436656). Patients were treated until disease progression, 
unacceptable toxicity, or withdrawal of informed consent. The primary objective was 
to determine the maximum tolerated dose (MTD) and/or recommended phase II 
dose (RP2D). Secondary objectives were to characterize the safety and tolerability 
and assess preliminary clinical antitumor activity and the pharmacokinetic profile of 
oral encorafenib. Exploratory objectives included assessing potential correlations of 
molecular status of RAF/MEK/MAPK and PI3K/AKT signaling molecules with clinical 
outcomes.  
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In the dose-escalation phase, patients were treated with either once-daily (QD) or 
twice-daily (BID) encorafenib in either microemulsion (50 or 100 mg QD) or capsule 
(50-700 mg QD, or 75-150 mg BID) formulation, administered in 28-day cycles. As 
the microemulsion and capsule formulations did not differ significantly in 
pharmacokinetic exposures or safety profiles at 50 and 100 mg QD, patients treated 
with the microemulsion were later transitioned to capsules at the same dose, for 
convenience. A Bayesian logistic regression model employing the escalation with 
overdose control (EWOC) principle was used to guide dose escalation and to 
estimate the MTD. The study started treating cohorts of 1–3 patients at the 
prespecified dose levels. Cohorts were expanded between 3–6 patients when dose-
limiting toxicities (DLTs) were identified, or  additional cohorts of 1–6 evaluable 
patients were added when a dose level showed signs of activity and satisfied EWOC 
criteria. The dose-escalation phase was continued until the MTD and/or RP2D of oral 
encorafenib was determined. The maximum tolerated dose was defined as the 
highest drug dose expected, based on the Bayesian logistic regression model, to not 
cause a DLT in more than 33% of the treated patients in the first cycle of encorafenib 
treatment 
 
The dose-expansion phase evaluated the safety and preliminary antitumor activity at 
the estimated MTD/RP2D in patients with locally advanced/metastatic melanoma 
(BRAFi-naive or BRAFi-pretreated). Most patients enrolled received either 300 or 
450 mg QD encorafenib. In addition, a small cohort of patients was treated with 
stepwise dosing of encorafenib from 300 mg (up to day [D] 15) to 450 mg (from D15 
onward if patients experienced no clinically significant grade 3/4 AEs at the lower 
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dose level). A third group of patients with metastatic colorectal cancer were enrolled 
in this trial (17) but their data will be published in a separate manuscript.  
Study procedures 
Safety assessments: Data regarding all adverse events (AEs) and serious AEs 
(SAEs) were collected, along with the severity and relationship to the study drug; 
AEs and SAEs were graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 (18). 
 
Efficacy assessments: All potential sites of tumor lesions were locally assessed by 
radiological techniques every 8 weeks per Response Evaluation Criteria In Solid 
Tumors (RECIST) v1.0 (19) for the dose-escalation phase and per RECIST v1.1 (20) 
for the dose-expansion phase. All complete and partial responses were confirmed by 
a second assessment at least 4 weeks later.  
 
Pharmacokinetic assessments: Blood samples for full pharmacokinetic profiles were 
collected on cycle 1 day 1 (C1D1), C1D8, and C1D15. Patients treated with stepwise 
dosing had samples collected on C1D1, C1D15, and C2D1 for dose expansion. 
Plasma encorafenib concentrations were measured using a validated liquid 
chromatography–tandem mass spectrometry assay.  
 
Somatic mutation and biomarker assessments: Representative tumor tissue was 
used to determine the mutation status of other genes relevant to RAF/MEK/ERK 
signaling to identify potential predictive markers of efficacy. Next-generation 
sequencing was conducted at Foundation Medicine using a T5a panel. 
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Statistical analysis 
The analysis was based on all patients’ data from the dose-escalation and dose-
expansion phases up to the time when all patients had completed at least 8 cycles of 
treatment or discontinued the study. Data are summarized with respect to 
demographic and baseline characteristics and efficacy and safety observations. 
Continuous variables are summarized as median and ranges. Categorical variables 
are expressed as frequencies and percentages. Progression-free survival (PFS) and 
overall survival (OS) were estimated using the Kaplan-Meier method and medians 
were reported with corresponding 95% CIs.   
 
RESULTS 
Preclinical Characterization 
Pharmacologic characterization of encorafenib in preclinical models 
Encorafenib inhibited BRAF V600E kinase activity in a biochemical assay at similar 
concentrations as dabrafenib and vemurafenib (Supplementary Table S1); however, 
the dissociation half-life was considerably increased (>30 hours) compared with 
dabrafenib (2 hours) and vemurafenib (0.5 hours; Supplementary Table S1 and 
Figure 1A). Washout experiments in A375 cells confirmed the long dissociation half-
life of encorafenib, as the phosphorylated ERK half maximal effective concentration 
(pERK EC50) only shifted 2-fold following washout compared with 14-fold and 23-fold 
for dabrafenib and vemurafenib, respectively (Supplementary Table S1). In a 
broader survey of BRAF V600-mutant cell lines, encorafenib was more potent at 
inhibiting proliferation, with most cell lines having IC50 <40 nM, while slightly higher 
concentrations of dabrafenib (<100 nM) and significantly higher concentrations of 
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vemurafenib (<1 μM) were required to inhibit proliferation of most cell lines 
(Supplemental Figure S1). 
 
Single-dose pharmacokinetic/pharmacodynamic studies in human melanoma 
xenograft models (BRAF V600E) showed that oral doses of encorafenib as low as 6 
mg/kg resulted in strong (75%) and sustained (>24 h) decreases in pERK (Figure 
1B), consistent with a prolonged dissociation half-life. Encorafenib induced tumor 
regression in multiple BRAF-mutant human tumor xenograft models grown in 
immune-compromised mice (Figures 1C and 1D). Although maximum encorafenib 
antitumor activity appeared to be achieved at 5 mg/kg BID (Figure 1E), higher doses 
were required to prevent the emergence of resistance and improve conditional 
survival (Figure 1F). 
 
Encorafenib was well tolerated, and exposure was dose proportional at all doses 
tested in mice (Supplemental Figure S2A, B). In order to determine the effect of 
encorafenib on cell proliferation that may potentially lead to SSC growth, epithelial 
hyperplasia and hyperkeratosis in the forestomach of mice were investigated over a 
dose range. Epithelial hyperplasia and hyperkeratosis were observed at very high 
encorafenib doses, in contrast to both vemurafenib (4/5 mice) and dabrafenib (5/5 
mice), with which gastric hyperplasia and hyperkeratosis were observed at clinically 
relevant doses (Supplementary Figure S2C). 
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Phase I Clinical Trial 
Patient disposition and characteristics 
Fifty-four patients with BRAF-mutant melanoma (25 BRAFi-naive and 29 BRAFi-
pretreated patients) were enrolled and treated in the dose-escalation phase. At the 
time of data analysis cutoff (18 August 2014), 49 patients had discontinued treatment 
(22 BRAFi-naive and 27 BRAFi-pretreated patients); the most common reason for 
treatment discontinuation was disease progression (n=41; 16 [64.0%] BRAFi-naive 
and 25 [86.2%] BRAFi-pretreated patients, respectively), followed by AEs (n=5; 
9.3%). Thirty-five additional patients (17 BRAFi-naive and 18 pretreated patients) 
were treated in the dose-expansion phase; 27 of these patients discontinued 
treatment by the time of data cutoff (11 BRAFi-naive and 16 BRAFi-pretreated 
patients). The most common reason for discontinuation was disease progression 
(n=17; 3 [17.6%] BRAFi-naive and 14 [77.8%] BRAFi-pretreated patients, 
respectively), followed by AEs (n=8; 22.9%). In BRAFi-pretreated patients, the 
median time from prior BRAFi treatment to the start of encorafenib was 38.5 days 
(range, 11-331). Patient characteristics are summarized in Table 1.  
Determination of MTD/RP2D 
The dose-determining set consisted of 49 patients treated across 11 dose levels. 
Seven patients (14.3%), of whom 3 were treated above 450 mg QD, experienced at 
least 1 DLT during cycle 1. The most frequent DLT was neuralgia (2 patients, 4.1%). 
All other DLTs occurred in 1 patient each (asthenia, confusional state, diarrhea, 
facial paresis, fatigue, headache, insomnia, musculoskeletal pain, neck pain, palmar-
plantar erythrodysesthesia [PPED] syndrome and rash; 2% each; Supplementary 
Table S2). Based on the Bayesian model, 450 mg QD was declared the MTD. 
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In the dose-expansion phase, 9 patients (33.3%), of whom 6 were treated at the 450 
mg QD MTD, experienced at least 1 DLT during cycle 1. At the MTD, DLTs included 
myalgia (33.3%), arthralgia (26.7%), fatigue (20.0%), asthenia (13.3%), seventh 
nerve paralysis (6.7%), and insomnia (6.7%; Supplementary Table S2). All DLTs 
were grade 3. Of these 9 patients, 7 required a dose reduction to 300 mg QD. At this 
time, the 450 mg QD MTD no longer met the EWOC criteria with a risk of excessive 
toxicity of 37.9%. Thus, the 300 mg QD dose level was better tolerated and declared 
the RP2D. The risk of excessive toxicity at 300 mg QD was 0.6%. 
Review of the BID dosing cohort revealed that the tolerability of this dosing schedule 
did not justify BID dosing in view of potentially reduced compliance compared with 
the QD dosing schedule. In conjunction with the known long dissociation half-life of 
encorafenib, a QD dosing regimen was selected for future dosing. 
Safety and tolerability 
Dose-escalation phase 
The median duration of exposure was 15.1 weeks (range, 0.7-142), and 5 patients 
had ongoing treatment at the time of data cutoff. All 54 patients experienced at least 
1 AE (Table 2). Grade 3/4 AEs were reported in 38 patients (70.4%); 6 patients 
(11.1%) had grade 4 AEs. The most common AEs (>40%) were PPED syndrome 
(51.9%), hyperkeratosis (50.0%), arthralgia (44.4%), nausea (44.4%), and pruritus 
(40.7%). Fifty-two patients had at least 1 AE suspected to be study drug related; of 
these, 18 patients (33.3%) had grade 3 AEs. Grade 3/4 study drug-related AEs 
reported (≥5% of patients) were fatigue (9.3%) and PPED syndrome (7.4%). Notably, 
the incidence of secondary neoplasms was low; SCC and keratoacanthoma were 
reported in 2 patients (3.7%) each. Three patients (5.6%) experienced facial paresis 
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(including facial paresis and seventh nerve paralysis) at 100-mg QD, 100-mg BID, 
and 450-mg QD dose levels. Pyrexia was reported in 2 patients (3.7%) and 
photosensitivity reactions were reported in 7 patients (13%). 
 
Five patients (9.3%) experienced AEs leading to treatment discontinuation; these 
were PPED syndrome (3.7%, 100 and 450 mg QD), headache (1.9%, 700 mg QD), 
hyperkeratosis (1.9%, 550 mg QD), and neuralgia (1.9%, 300 mg QD). Eleven on-
treatment deaths (defined as occurring during treatment or within 30 days of the last 
dose of study medication) were reported. One death, which was due to general 
health deterioration, was considered to be related to the study treatment by the study 
investigator; however, the role of disease progression, which was documented 19 
days prior to death, may also be a plausible explanation for the outcome. The patient 
had ongoing events at the time of death, including dysphagia, confusional state, and 
a new melanoma. The remaining 10 on-treatment deaths (1 during treatment and 9 
within 30 days of the last encorafenib dose) were due to progressive disease and 
unrelated to the study treatment. 
Dose-expansion phase 
The median duration of exposure for all patients was 12.1 weeks (range, 0.1-90.7), 
and 8 patients had treatment ongoing at the time of data cutoff. In patients who had 
been pretreated with a BRAFi, exposure duration was 8.9 weeks (range, 0.4-90.7) in 
the MTD group and 5.6 weeks (range, 0.4-10.9) in the RP2D group. For BRAFi-naive 
patients this was 6.3 weeks (range, 0.1-71.7) in the MTD group and 38.6 weeks 
(range, 0.4-53.9) in the RP2D group. 
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AEs experienced in the dose-expansion phase were similar to those experienced in 
the dose-escalation phase (Table 2). Thirty-four (97.1%) patients had at least 1 AE 
suspected to be study drug-related. The most frequent study drug-related AEs 
(>40%) were myalgia (62.9%), nausea (57.1%), PPED syndrome (54.3%), arthralgia 
(48.6%), vomiting (45.7%), alopecia (42.9%), dry skin (42.9%), and insomnia 
(40.0%). One patient (2.9%) experienced SCC of the head and neck, and 
keratoacanthoma was not observed. Four patients (11.4%) experienced facial 
paresis (seventh nerve paralysis) at 300 mg QD (n=1), at 450 mg QD (n=2), and in 
the stepwise group (n=1). Pyrexia was reported in 2 patients (5.7%), and 
photosensitivity reactions were reported in 1 patient (2.9%). 
 
Eight patients (22.9%) had AEs leading to discontinuation of study drug; the most 
common AEs were arthralgia and myalgia (5.7% each). Two on-treatment deaths 
(both within 30 days of the last dose of encorafenib) were reported and were not 
considered to be related to study treatment. 
Pharmacokinetics  
Encorafenib was rapidly absorbed and detectable in plasma at 0.5 h postdose and 
across all dose levels peaked (Tmax) at approximately 2 h (Figure 2). Terminal half-
life (T1/2) was short (2.9-4.4 h), remained constant across doses, and was similar 
between C1D1 and C1D15 (Supplementary Table S3). Plasma concentrations of 
encorafenib were lower on C1D15 than C1D1 across all dose levels, suggesting 
time-dependent pharmacokinetics. Plasma clearance was increased 2-fold between 
C1D1 and C1D15, while the area under the plasma concentration-time curve for a 
dosing interval (AUCτ) and maximum plasma concentration (Cmax) showed that 
systemic exposure was also lower at C1D15 (Supplementary Table S3), possibly 
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due to autoinduction via the CYP3A4 pathway. Trough plasma concentrations did 
not show an appreciable difference by C2D1, suggesting that steady-state conditions 
had been reached by C1D15. Mixed-effect modeling on QD capsule data of C1D1 
and C1D15 confirmed that AUC and Cmax were approximately dose proportional over 
the complete dose range (Supplementary Table S3).  
Efficacy 
In the dose-escalation phase, the overall response rates (ORRs) for BRAFi-naive 
and BRAFi-pretreated patients were 60.0% and 10.3%, respectively (Table 3, Figure 
3A). In the dose-expansion phase, the ORRs were 60.0% and 22.2% for BRAFi-
naive and BRAFi-pretreated patients, respectively (Table 3; Figure 3B). PFS and OS 
were assessed for patients in the dose-expansion phase only. Median PFS for 
BRAFi-naive patients was 12.4 months (95% CI, 7.4-NR), and the PFS rate at 6 
months was 91.7% (95% CI, 76.0-100). Median PFS for BRAFi-pretreated patients 
was 1.9 months (95% CI, 0.9-3.7), with a PFS rate at 6 months of 11.8% (95% CI, 
0.0-27.1; Figure 3C). Median OS was not reached for BRAFi-naive patients and was 
9.07 months (95% CI, 3.68-10.84) for BRAFi-pretreated patients (Figure 3D).  
Biomarker analysis 
The mutation status of archival or fresh tumor samples collected at baseline was 
analyzed centrally by next-generation sequencing. No correlation was observed 
between the best percentage change from baseline and mutation status 
(Supplementary Figure S3A and B).  
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DISCUSSION 
Preclinical studies demonstrate that encorafenib is more potent and has prolonged 
pharmacodynamic activity compared with approved BRAF inhibitors vemurafenib 
and dabrafenib. Antitumor activity of encorafenib was demonstrated in human BRAF 
V600E-mutant melanoma xenografts at doses as low as 5 mg/kg; however, higher 
doses were required to prevent the emergence of resistance in this model. Positive 
preclinical findings led to further investigation of encorafenib in clinical trials. Data 
from a more comprehensive investigation of the preclinical comparative 
pharmarmacology of encorafenib and other BRAF inhibitors are in preparation for 
publication. 
 
The primary objective of this phase I study was to determine the MTD and/or RP2D 
of encorafenib. The MTD was established at 450 mg QD based on data from the 
dose-escalation phase; however, after reviewing the safety and tolerability data in 
the dose-expansion phase, the MTD was not considered to be a viable RP2D 
because 7 of 9 patients who exhibited a DLT during the first cycle required a dose 
reduction to 300 mg QD. Therefore, the 300-mg QD dose level was declared the 
RP2D. Review of the overall safety profile of the 450-mg QD and 300-mg QD doses 
continued to show meaningfully higher rates of DLTs and grade 3 AEs at the MTD, 
supporting 300 mg QD as the RP2D for encorafenib as a single agent. 
 
Encorafenib showed signs of promising activity in this study, with ORRs in the dose-
expansion phase of 60% in patients with melanoma who were BRAFi-naive. Minimal 
efficacy was seen in patients who received prior BRAFi treatment. BRAFi-pretreated 
patients received encorafenib between 1.5-47 weeks following their BRAFi 
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treatment. Objective responses to BRAFi retreatment have been reported in patients 
progressing on BRAFi therapy following a treatment break (21, 22). Therefore, 
treatment interruption may account for some of the responses observed in pretreated 
patients in this study due to removal of the selective pressure of MAPK inhibition. 
Correlative analyses between the length of the BRAFi treatment-break interval and 
response to subsequent BRAFi will help further understand tumor response 
dynamics. Encorafenib showed durable response in BRAFi-naive patients, with a 
median PFS of 12.4 months—longer than that reported in vemurafenib (5.3 months) 
(23) and dabrafenib (4.5-6.2 months) in the same setting (24). Data from the 
randomized COLUMBUS trial confirm this observation (25). 
 
Encorafenib was well tolerated, with most AEs being grade 2 or lower in severity. 
Single-agent BRAFis have been associated with characteristic AEs, which are 
proposed to be the result of aberrant wild-type BRAF/CRAF activation. Dermatologic 
events were among the most common AEs observed in the dose-escalation and  
-expansion phases. PPED and hyperkeratosis were reported in over 40% of patients, 
higher than the rates reported with the approved BRAF inhibitors. Although 
hyperkeratosis is a characteristic and diagnostic feature of PPED according to the 
NCI CTCAE v4.0 reporting criteria (18), hyperkeratosis was often experienced in 
locations other than the hands and feet. Cutaneous SCC has been reported in  
12%-21% of patients with melanoma following treatment with vemurafenib 
monotherapy (23, 26, 27) and in 9%-19% of patients following dabrafenib 
monotherapy (11, 24, 28), in contrast to the low rates (3%-4%) observed in this 
study. These observations are intriguing given the lower rate of hyperplasia 
observed in the gastric epithelium of mice treated with encorafenib. A recent study 
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profiling the paradoxical activation of ERK across the BRAF inhibitors vemurafenib, 
dabrafenib, and encorafenib suggests that differences in the potency of pERK 
induction in HRASmut, BRAFwt keratinocytes relative to the potency of pERK inhibition 
in BRAF V600E melanoma cells may account for the varying rates of cutaneous 
SCC between the compounds (29).  
 
Facial paresis has been reported in cases of patients treated with vemurafenib (30, 
31). Symptoms typically resolve when treatment is stopped and may be resolved 
with steroid treatment, suggesting a possible autoimmune mechanistic trigger. Facial 
paresis (regardless of causality) was observed in 7 patients (7.9%) treated with 
encorafenib. The low rates of pyrexia, photosensitivity, and cutaneous SCC suggest 
a tolerability profile that is different from either vemurafenib or dabrafenib (5, 7). 
Further studies are needed to better understand the mechanisms that underlie these 
differences, which may include on-target and off-target effects (32). 
 
It is important to note that the standard of care with BRAF-targeted therapy has 
changed dramatically since the commencement of this study. Specifically, there are 
now 3 randomized trials demonstrating superior response rates, PFS, and OS in 
patients receiving combinations of BRAF and MEK inhibitors (dabrafenib plus 
trametinib, and vemurafenib plus cobimetinib) compared with single-agent BRAFi 
therapy (11-13, 28), which led to the approval of these combinations for the 
treatment of patients with unresectable or metastatic melanoma with a BRAF V600E 
or V600K mutation. Preliminary results from combination studies have suggested 
that pairing encorafenib with the MEK inhibitor binimetinib mitigates some 
dermatologic AEs that were associated with single-agent encorafenib, a finding that 
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has also been reported with the combination of dabrafenib and trametinib (33), and 
appears to be associated with efficacy comparable to other BRAF/MEK inhibitor 
combinations (28, 34, 35). The efficacy and safety of encorafenib is currently being 
further investigated in combination with binimetinib, and compared with that of 
encorafenib or vemurafenib alone, in an ongoing phase III study (COLUMBUS, 
NCT01909453) (25).  
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Table 1. Baseline patient and disease characteristics 
 
Characteristic 
Dose Escalation Dose Expansion 
BRAFi 
Naive 
(n=25) 
BRAFi 
Pretreated  
(n=29) 
BRAFi 
Naive  
(n=15) 
BRAFi 
Pretreated  
(n=18) 
All 
Melanoma*  
(N=35) 
Median age (range), 
years 
51.0  
(33-70) 
50.0  
(22-78) 
61.0  
(43-79) 
54.0  
(26-74) 
59.0  
(26-79) 
Sex, n (%) 
Female 
Male 
 
8 (32) 
17 (68) 
 
10 (35) 
19 (65) 
 
5 (33) 
10 (67) 
 
14 (78) 
4 (22) 
 
20 (57) 
15 (43) 
WHO performance 
status, n (%) 
0 
1 
2 
 
 
19 (76) 
5 (20) 
1 (4) 
 
 
16 (55) 
12 (41) 
1 (3) 
 
 
12 (80) 
3 (20) 
0 (0) 
 
 
8 (44) 
10 (56) 
0 (0) 
 
 
20 (57) 
15 (43) 
0 (0) 
BRAF V600 mutation 
status, n (%) 
V600E 
Other 
 
 
23 (92) 
2 (8) 
 
 
26 (90) 
3 (10) 
 
 
13 (87) 
2 (13) 
 
 
17 (94) 
1 (6) 
 
 
31 (89) 
4 (11) 
LDH at baseline, n (%) 
≤ULN 
>ULN 
 
16 (64) 
9 (36) 
 
16 (55) 
13 (45) 
 
10 (67) 
5 (33) 
 
4 (22) 
14 (78) 
 
14 (40) 
21 (60) 
Stage at current 
diagnosis, n (%) 
Stage IIIb 
Stage IIIc 
Stage Iva 
Stage IVb 
Stage IVc 
 
 
1 (4) 
0 (0) 
2 (8) 
0 (0) 
22 (88) 
 
 
0 (0) 
0 (0) 
1 (3) 
4 (14) 
24 (83) 
 
 
1 (7) 
1 (7) 
2 (13) 
4 (27) 
7 (47) 
 
 
0 (0) 
0 (0) 
0 (0) 
1 (6) 
17 (94) 
 
 
1 (3) 
1 (3) 
2 (6) 
5 (14) 
26 (74) 
Previous BRAFi 
treatment, n (%) 
 29 (100)  18 (100)  
Vemurafenib  28 (97)  16 (89)  
Dabrafenib  0 (0)  2 (11)  
Investigational 
BRAFi 
 1 (3)  0 (0)  
Median time between 
discontinuation of 
BRAFi and study start,  
days (range) 
 26  
(12-319) 
 38.5  
(11-331) 
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Table 2. Adverse events occurring in ≥30% of patients in the dose-expansion phase 
 
Adverse Event 
BRAFi Naive 
(n=15), n (%) 
 
 
BRAFi Pretreated 
(n=18), n (%) 
All Melanoma*  
(N=35), n (%) 
All 
Grades 
Grade 
3/4 
 All 
Grades 
Grade 3/4 All 
Grades 
Grade 3/4 
Irrespective of study drug relationship 
Nausea 9 (60.0) 1 (6.7)  13 (72.2) 3 (16.7) 23 (65.7) 4 (11.4) 
Myalgia 8 (53.3) 2 (13.3)  13 (72.2) 3 (16.7) 22 (62.9) 5 (14.3) 
PPED 
syndrome 
6 (40.0) 0 (0.0)  11 (61.1) 3 (16.7) 19 (54.3) 4 (11.4) 
Arthralgia 6 (40.0) 3 (20.0)  9 (50.0) 3 (16.7) 17 (48.6) 7 (20.0) 
Vomiting 5 (33.3) 1 (6.7)  10 (55.6) 2 (11.1) 17 (48.6) 3 (8.6) 
Insomnia 4 (26.7) 1 (6.7)  10 (55.6) 1 (5.6) 16 (45.7) 2 (5.7) 
Alopecia 7 (46.7) 0 (0)  8 (44.4) 0 (0) 15 (42.9) 0 (0) 
Dry skin 6 (40.0) 0 (0.0)  9 (50.0) 1 (5.6) 15 (42.9) 1 (2.9) 
Hyperkeratosis 6 (40.0) 1 (6.7)  6 (33.3) 0 (0) 14 (40.0) 1 (2.9) 
Headache 4 (26.7) 0 (0)  9 (50.0) 2 (11.1) 13 (37.1) 2 (5.7) 
Keratosis pilaris 3 (20.0) 0 (0)  9 (50.0) 2 (11.1) 13 (37.1) 2 (5.7) 
Pruritus 5 (33.3) 0 (0)  6 (33.3) 1 (5.6) 13 (37.1) 1 (2.9) 
Asthenia 1 (6.7) 0 (0)  9 (50.0) 3 (16.7) 11 (31.4) 3 (8.6) 
Constipation 5 (33.3) 0 (0)  5 (27.8) 0 (0) 11 (31.4) 0 (0) 
Suspected study drug–related 
Myalgia 8 (53.3) 2 (13.3)  13 (72.2) 3 (16.7) 22 (62.9) 5 (14.3) 
Nausea 8 (53.3) 1 (6.7)  11 (61.1) 1 (5.6) 20 (57.1) 2 (5.7) 
PPED 
syndrome 
6 (40.0) 0 (0)  11 (61.1) 3 (16.7) 19 (54.3) 4 (11.4) 
Arthralgia 6 (40.0) 3 (20.0)  9 (50.0) 3 (16.7) 17 (48.6) 7 (20.0) 
Vomiting 5 (33.3) 1 (6.7)  9 (50.0) 2 (11.1) 16 (45.7) 3 (8.6) 
Alopecia 7 (46.7) 0 (0)  8 (44.4) 0 (0) 15 (42.9) 0 (0) 
Dry skin 6 (40.0) 0 (0)  9 (50.0) 1 (5.6) 15 (42.9) 1 (2.9) 
Insomnia 4 (26.7) 1 (6.7)  10 (55.6) 1 (5.6) 14 (40.0) 2 (5.7) 
Hyperkeratosis 6 (40.0) 1 (6.7)  5 (27.8) 0 (0) 13 (37.1) 1 (2.9) 
Keratosis pilaris 3 (20.0) 0 (0)  9 (50.0) 2 (11.1) 13 (37.1) 2 (5.7) 
Pruritus 5 (33.3) 0 (0)  5 (27.8) 1 (5.6) 12 (34.3) 1 (2.9) 
Asthenia 1 (6.7) 0 (0)  9 (50.0) 3 (16.7) 11 (31.4) 3 (8.6) 
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Table 3. Summary of best overall response for patients in the dose-escalation and 
dose-expansion phases 
 
Best Overall 
Response 
Dose Escalation Dose Expansion 
BRAFi 
Naive 
(n=25), n 
(%) 
BRAFi 
Pretreated  
(n=29), n 
(%) 
BRAFi 
Naive  
(n=15), n 
(%) 
BRAFi 
Pretreated  
(n=18), n 
(%) 
All 
Melanoma*  
(N=35), n 
(%) 
CR 2 (8.0) 1 (3.4) 1 (6.7) 0 1 (2.9) 
PR 
Unconfirmed CR† 
13 (52.0) 
0 
2 (6.9) 
0 
8 (53.3) 
1 (6.7) 
4 (22.2) 
0 
13 (37.1) 
1 (2.9) 
Stable disease 
Unconfirmed 
CR/PR‡ 
5 (20.0) 
1 (4.0) 
10 (34.5) 
0 
1 (6.7) 
0 
2 (11.1) 
1 (5.6) 
4 (11.4) 
1 (2.9) 
Progressive disease 
Unconfirmed 
CR/PR 
0 
0 
14 (48.3) 
0 
1 (6.7) 
0 
10 (55.6) 
0 
11 (31.4) 
0  
Unknown 
Unconfirmed 
CR/PR§ 
5 (20.0) 
1 (4.0) 
2 (6.9) 
0 
4 (26.7) 
1 (6.7) 
2 (11.1) 
0 
6 (17.1) 
1 (2.9) 
ORR 
95% CI 
15 (60.0) 
38.7-78.9 
3 (10.3) 
2.2-27.4 
9 (60.0) 
32.3-83.7 
4 (22.2) 
6.4-47.6 
14 (40.0) 
23.9-57.9 
Disease control rate 
95% CI 
20 (80.0) 
59.3-93.2 
13 (44.8) 
26.4-64.3 
10 (66.7) 
38.4-88.2 
6 (33.3) 
13.3-59.0 
18 (51.4) 
34.0-68.6 
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Table Legends 
Table 1. Baseline patient and disease characteristics 
BRAFi, BRAF inhibitor; LDH, lactate dehydrogenase; ULN, upper limit of the normal 
range; WHO, World Health Organization. 
*Includes 2 patients in the stepwise group; 300 mg (first 15 days of treatment) to 450 
mg (from day 15 onward if patients experienced no clinically significant grade 3 or 4 
adverse events at the lower dose level). 
 
Table 2. Adverse events occurring in ≥30% of patients in the dose-expansion 
phase 
PPED, palmar-plantar erythrodysesthesia. 
*Includes 2 patients in the stepwise group; 300 mg (first 15 days of treatment) to 450 
mg (from day 15 onward if patients experienced no clinically significant grade 3 or 4 
adverse events at the lower dose level). 
 
Table 3. Summary of best overall response for patients in the dose-escalation 
and dose-expansion phases 
CR, complete response; ORR, overall response rate; PR, partial response. 
*Includes 2 patients in the stepwise group; 300 mg (first 15 days of treatment) to 450 
mg (from day 15 onward if patients experienced no clinically significant grade 3 or 4 
adverse events at the lower dose level). 
†Unconfirmed CR due to no confirmatory scan before data cutoff. 
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‡Unconfirmed CR/PR due to PR followed by progressive disease at the confirmatory 
scan. 
§Unconfirmed CR/PR due to PR followed by patient discontinuation due to AE. 
 
Figure Legends 
Figure 1. Pharmacologic characterization of encorafenib  
(A) Impact of BRAF inhibitors on phosphorylated MEK (pMEK) in BRAF V600E-
mutant cells; (B) Tumor pERK inhibition and plasma encorafenib concentration 
across varying doses (0.6-60 mg/kg) of encorafenib. Female nude mice bearing 
A375 (BRAF V600E) human melanoma tumor xenografts were given a single oral 
dose of vehicle or encorafenib, and plasma and tumor samples were collected at 
predetermined time points. Phosphorylated ERK levels were measured in tumor 
lysates using a Meso Scale Discovery assay (normalized to total ERK) and the 
percent of inhibition was plotted relative to vehicle controls; (C) Efficacy of 
encorafenib, dabrafenib, and vemurafenib in the A375 human melanoma tumor 
xenograft model grown in nude mice (n=5 per group). Encorafenib and vemurafenib 
were dosed twice daily on an 8/16 hour interval and dabrafenib was dosed QD by 
oral gavage for 14 days. Tumor volume and body weight were measured twice per 
week. No signs of toxicity or mortality were observed (see Supplementary Figure 
S2A); (D) Efficacy of encorafenib in the HMEX1906 primary human melanoma 
xenograft model grown in nude mice (n=8 per group); (E) Waterfall plot of change in 
volume for each tumor in each treatment group from the experiment depicted in 1D. 
Each bar represents the maximum treatment effect observed for each mouse; (F) 
Mice from the experiment depicted in 1D were dosed continually, and the endpoint of 
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conditional survival was marked on the day at which each tumor regrew to its 
predose baseline.  
BID, twice daily; QD, once daily; RFU, relative fluorescence units. 
 
Figure 2. Median semilogarithmic concentration-time profiles for plasma 
concentration of encorafenib by time and treatment group in the dose-
escalation phase 
cps, capsule; m, microemulsion; QD, once daily. 
 
Figure 3. Efficacy of encorafenib by treatment group 
Best percentage change in sum of longest diameters in target lesion from baseline 
by treatment group in the dose-escalation (A) and dose-expansion phases (B); 
Kaplan-Meier plot of progression-free survival (C) and overall survival (D) by patient 
group in the dose-escalation phase. 
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